Omicron XBB.1.16-Adapted Vaccine for COVID-19

(1) Background: The global coronavirus disease 2019 vaccination adapts to protect populations from emerging variants. This communication presents interim findings from the new Omicron XBB.1.16-adapted PHH-1V81 protein-based vaccine compared to an XBB.1.5-adapted mRNA vaccine against various acute re...

Full description

Bibliographic Details
Authors: López Fernández, María Jesús|||0000-0001-5714-0125, Narejos, Silvia, Castro, Antoni, Echave-Sustaeta, José María, Forner, Maria Jose|||0000-0002-6786-6760, Arana-Arri, Eunate|||0000-0001-9759-333X, Moltó, José|||0000-0003-4564-1963, Bernard Rosa, Laia|||0000-0002-8137-640X, Pérez-Caballero, Raúl|||0000-0001-7063-5958, Prado, Julia G.|||0000-0002-5439-4645, Raïch-Regué, Dàlia|||0000-0001-7656-5700, Boreika, Rytis|||0000-0001-6720-1577, Izquierdo Useros, Nuria|||0000-0002-1039-1821, Trinité, Benjamin|||0000-0003-3809-042X, Blanco, Julià|||0000-0002-2225-0217, Puig-Barberà, Joan|||0000-0001-5783-0409, Natalini Martínez, Silvina|||0000-0001-5257-547X
Format: article
Publication Date:2024
Country:España
Institution:Universitat Autònoma de Barcelona
Repository:Dipòsit Digital de Documents de la UAB
Language:English
OAI Identifier:oai:ddd.uab.cat:311531
Online Access:https://ddd.uab.cat/record/311531
https://dx.doi.org/urn:doi:10.3390/vaccines12080840
Access Level:Open access
Keyword:JN.1
XBB.1.16
Adapted vaccine
SARS-CoV-2 vaccine
Adjuvanted protein vaccine
Booster vaccine
COVID-19
Description
Summary:(1) Background: The global coronavirus disease 2019 vaccination adapts to protect populations from emerging variants. This communication presents interim findings from the new Omicron XBB.1.16-adapted PHH-1V81 protein-based vaccine compared to an XBB.1.5-adapted mRNA vaccine against various acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains. (2) Methods: In a Phase IIb/III pivotal trial, adults previously vaccinated with a primary scheme and at least one booster dose of an EU-approved mRNA vaccine randomly received either the PHH-1V81 or BNT162b2 XBB.1.5 vaccine booster as a single dose. The primary efficacy endpoint assessed neutralization titers against the Omicron XBB.1.16 variant at day 14. Secondary endpoints evaluated neutralization titers and cellular immunity against different variants. Safety endpoints comprised solicited reactions up to day 7 post-vaccination and serious adverse events until the cut-off date of the interim analysis. Changes in humoral responses were assessed by pseudovirion-based or virus neutralization assays. (3) Results: At the cut-off date, immunogenicity assessments included 599 participants. Both boosters elicited neutralizing antibodies against XBB.1.16, XBB.1.5, and JN.1, with PHH-1V81 inducing a higher response for all variants. The PHH-1V8 booster triggers a superior neutralizing antibody response against XBB variants compared to the mRNA vaccine. A subgroup analysis consistently revealed higher neutralizing antibody responses with PHH-1V81 across age groups, SARS-CoV-2 infection history, and the number of prior vaccination shots. A safety analysis (n = 607) at the day 14 visit revealed favorable safety profiles without any serious vaccine-related adverse events. (4) Conclusions: PHH-1V81 demonstrates superiority on humoral immunogenicity compared to the mRNA vaccine against XBB variants and non-inferiority against JN.1 with a favorable safety profile and lower reactogenicity, confirming its potential as a vaccine candidate.

Similar Items